Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Issues Revised GMP Draft; Compliance Expected In Stages

This article was originally published in The Tan Sheet

Executive Summary

China's latest draft guideline on good manufacturing practices for drugs offers clarity on a few key points but still leaves huge gaps that need to be filled
Advertisement

Related Content

China's Aging Population Spurs OTC Sales, Looks For More Options
China's Aging Population Spurs OTC Sales, Looks For More Options
China's Aging Population Spurs OTC Sales, Looks For More Options
U.S. Pharmacopeia Moves Melamine Testing Into The 21st Century
China Taking Regulatory Route To Tighten Oversight Of Health Care Sector
China Taking Regulatory Route To Tighten Oversight Of Health Care Sector

Topics

Advertisement
UsernamePublicRestriction

Register

PS103654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel